Latest Lead News

Nyrada has completed its Phase I trial for Xolatryp, confirming safety and predictable pharmacokinetics, while securing AU$8.25 million to fund an upcoming Phase IIa trial targeting heart attack patients.

Catapult Sports has launched a Share Purchase Plan (SPP) offering eligible shareholders in Australia and New Zealand the chance to buy shares at a discount, following a recent A$130 million institutional placement and its acquisition of IMPECT GmbH.

Catapult Sports has launched a Share Purchase Plan (SPP) offering eligible shareholders in Australia and New Zealand the chance to buy up to A$30,000 in shares at a discount, following a successful A$130 million institutional placement. The capital raise supports the recent acquisition of IMPECT GmbH and future strategic opportunities.

Astron Limited and Energy Fuels have received a conditional Letter of Support from Export Finance Australia for up to A$80 million in senior debt financing, advancing the Donald Rare Earth and Mineral Sands Project toward production.

Latrobe Magnesium Limited has announced a fully underwritten $10 million equity raise through a $6 million placement and a $4 million rights issue to fund its magnesium production expansion. The capital will support the commissioning of its Demonstration Plant and advance plans for a 10,000 tonne commercial facility.

Imagion Biosystems has made significant strides toward filing an IND application for its MagSense® HER2 breast cancer imaging agent, supported by positive FDA feedback and a recent $3.5 million capital raise to fund upcoming clinical trials.

Tasman Resources has raised $2 million through a two-tranche placement to fund a promising drilling campaign at Parkinson Dam and broaden its project portfolio, alongside appointing a new director to steer its strategic ambitions.

VHM Limited has obtained conditional financial backing of up to A$379 million from Export Finance Australia and the US Export-Import Bank to advance its Goschen Rare Earths and Mineral Sands Project in Victoria.

Helloworld Travel Limited has completed its acquisition of the remaining 50% stake in Mobile Travel Holdings, fully owning the mobile travel agency and significantly boosting its transaction volume.

PYC Therapeutics has kicked off a global Phase 1b repeat dose study of its investigational drug PYC-001 targeting Autosomal Dominant Optic Atrophy, a rare genetic eye disease with no current treatments. Initial dosing has begun, with key data expected in the second half of 2026.

Pure Hydrogen Corporation has locked in a $2.5 million loan facility to accelerate its clean energy vehicle rollout, aiming to capitalise on a growing sales pipeline in Australia and the US.

Neurizon Therapeutics has been granted a key Australian patent for its lead drug candidate NUZ-001, extending protection for treatments targeting ALS, Alzheimer's, and other neurodegenerative diseases through 2041. This milestone complements earlier US patent grants and sets the stage for upcoming clinical trials.